LeonaBio (LONA) Depreciation & Amortization (CF) (2020 - 2026)
LeonaBio (LONA) reported Depreciation & Amortization (CF) of $231000.0 for Q1 2026, down 4.94% year-over-year from $243000.0 in Q1 2025, and down 15.07% on a QoQ basis from $272000.0 in Q4 2025.
LeonaBio (LONA) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $231000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 4.94% year-over-year to $231000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $903000.0 (up 1.92% YoY) and the FY2025 annual result came in at $972000.0, changed 0.21% from the prior year.
- Depreciation & Amortization (CF) declined to $231000.0 in Q1 2026 per LONA's latest filing, from $272000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $272000.0 in Q4 2025 and bottomed at $154000.0 in Q1 2022.
- The 5-year median for Depreciation & Amortization (CF) is $236000.0 (2023), against an average of $226176.5.
- The widest annual swing landed in 2022, when Depreciation & Amortization (CF) jumped 89.68%; it then retreated 18.03% in 2024.
- Tracing LONA's Depreciation & Amortization (CF) over 5 years: stood at $239000.0 in 2022, then increased by 2.51% to $245000.0 in 2023, then retreated by 0.82% to $243000.0 in 2024, then climbed by 11.93% to $272000.0 in 2025, then dropped by 15.07% to $231000.0 in 2026.
- Per Business Quant, the three latest LONA Depreciation & Amortization (CF) figures stand at $231000.0 (Q1 2026), $272000.0 (Q4 2025), and $200000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 1,395.22 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 55.90 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 123.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 13.55 Mn |
| 10 | LeonaBio | 181.52 Mn | 113.84 Mn | - | 231,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 231,000.00 |
| Mar 31, 2026 | 231,000.00 |
| Dec 31, 2025 | 272,000.00 |
| Dec 31, 2025 | 272,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 200,000.00 |
| Mar 31, 2025 | 243,000.00 |
| Mar 31, 2025 | 243,000.00 |
| Dec 31, 2024 | 243,000.00 |
| Dec 31, 2024 | 243,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Sep 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Jun 30, 2024 | 200,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Mar 31, 2024 | 242,000.00 |
| Dec 31, 2023 | 245,000.00 |
| Dec 31, 2023 | 245,000.00 |
| Sep 30, 2023 | 244,000.00 |
| Sep 30, 2023 | 244,000.00 |
| Jun 30, 2023 | 244,000.00 |
| Jun 30, 2023 | 244,000.00 |
| Mar 31, 2023 | 236,000.00 |
| Mar 31, 2023 | 236,000.00 |
| Dec 31, 2022 | 239,000.00 |
| Dec 31, 2022 | 239,000.00 |
| Sep 30, 2022 | 231,000.00 |
| Sep 30, 2022 | 231,000.00 |
| Jun 30, 2022 | 221,000.00 |
| Jun 30, 2022 | 221,000.00 |
| Mar 31, 2022 | 154,000.00 |
| Mar 31, 2022 | 154,000.00 |
| Dec 31, 2021 | 126,000.00 |
| Dec 31, 2021 | 126,000.00 |
| Sep 30, 2021 | 123,000.00 |
| Sep 30, 2021 | 123,000.00 |
| Jun 30, 2021 | 118,000.00 |
| Jun 30, 2021 | 118,000.00 |
| Mar 31, 2021 | 112,000.00 |
| Mar 31, 2021 | 112,000.00 |
| Dec 31, 2020 | 2,000.00 |
| Dec 31, 2020 | 2,000.00 |